Can’t find what you’re looking for? Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Order Online! Now! Get your $50 coupon for online order. 
Order Online! Now! Get your $50 coupon for online order.
Get your basement membrane extract free sample to test now! Get your basement membrane extract free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CHEK-ATF103 | Human | Human GCGR (Luc) HEK293 Reporter Cell | |||
| GCR-H52P5 | Human | Human GCGR / Glucagon receptor Full Length Protein (VLP) |
|
||
| GCR-H53H3 | Human | Human GCGR / Glucagon receptor Protein, Fc Tag (MALS verified) |  |
|
|
| GCR-H82E3 | Human | Biotinylated Human GCGR / Glucagon receptor Protein, His,Avitag™ (MALS verified) |  |
|
|
| GCR-M5254 | Mouse | Mouse GCGR / Glucagon receptor Protein, Fc Tag |  |
|
|
| GCR-H52H3 | Human | Human GCGR / Glucagon receptor Protein, His Tag (MALS verified) |  |
|
|
Expression analysis of human GCGR on Human GCGR (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human GCGR (Luc) HEK293 Reporter Cell or negative control cell using Alexa Fluor® 488-labeled anti-human GCGR antibody.
Human GCGR Protein, Fc Tag (Cat. No. GCR-H53H3) immobilized on CM5 Chip can bind GLP-1 (7-37) with an affinity constant of 51.1 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Glucagon (rDNA origin, Novo Nordisk) | GL-G | Approved | Novo Nordisk A/S | GlucaGen, Glucagon G | United States | Hypoglycemia | Novo Nordisk A/S | 1998-06-22 | Diabetes Mellitus, Type 1; Hypoglycemia; Obesity | Details |
| Glucagon intranasal (Eli Lilly/Locemia Solutions) | AMG504-1; LY-900018 | Approved | Amg Medical, Locemia Solutions | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemia; Diabetes Mellitus | Details | |||||
| Glucagon (Xeris Pharmaceuticals) | Approved | Xeris Pharmaceuticals Inc | Gvoke | United States | Hypoglycemia | Xeris Pharmaceuticals Inc | 1960-01-01 | Hypoglycemia; Hyperinsulinism | Details | |
| Glucagon (rDNA origin, Lilly) | Approved | Eli Lilly And Company | Glucagon | United States | Hypoglycemia | Eli Lilly And Company | 1998-09-11 | Diabetes Mellitus, Type 1; Hypoglycemia; Insulin Resistance; Obesity | Details | |
| Glucagon | MP-123456B | Approved | Eli Lilly And Company | Baqsimi, Ogluo | EU | Hypoglycemia | Eli Lilly Nederland BV | 1960-11-14 | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemia | Details |
| Dasiglucagon | ZP-GA-1; ZP-4207 | Approved | Zealand Pharma A/S | Zegalogue | United States | Hypoglycemia | Zealand Pharma Us Inc | 2021-03-22 | Congenital Hyperinsulinism; Diabetes Mellitus, Type 1; Hypoglycemia; Hyperinsulinism; Glucose Metabolism Disorders | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Oxyntomodulin long-acting (Pharmsynthez/Xenetic Biosciences) | Phase 2 Clinical | Pharmsynthez, Xenetic Biosciences Inc | Diabetes Mellitus, Type 2; Obesity | Details | |
| PRT-001 | PRT-001 | Phase 3 Clinical | Particle Therapeutics | Hypoglycemia | Details |
| PRT-003 | PRT-003 | Phase 1 Clinical | Particle Therapeutics | Details | |
| IONIS-GCGRRx | IONIS-GCGRRx; ISIS-449884; ISISGCGRRx | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Diabetes Mellitus, Type 2 | Details |
| Efocipegtrutide | HM-15211 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Non-alcoholic Fatty Liver Disease; Obesity | Details |
| retatrutide | LY-3437943 | Phase 2 Clinical | Eli Lilly And Company | Diabetes Mellitus, Type 2; Renal Insufficiency; Obesity; Overweight | Details |
| HM-15136 | HM-15136 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Congenital Hyperinsulinism; Diabetes Mellitus, Type 2 | Details |
| TB-001 | TB001; TB-001 | Phase 1 Clinical | Shenzhen Tuwei Anchuang Technology Development Co Ltd | Non-alcoholic Fatty Liver Disease; Liver Cirrhosis | Details |
| Efinopegdutide | JNJ-64565111; HM-12525A; JNJ-5111; MK-6024 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease; Obesity; Kidney Failure, Chronic | Details |
| RBD-4988 | RBD-4988 | Phase 2 Clinical | Suzhou Ruibo Biological Technology Co Ltd | Diabetes Mellitus, Type 2 | Details |
| Pemvidutide | ALT-801(Altimmune); SP-1373; VPD-107 | Phase 2 Clinical | Velocity Pharmaceutical Development | Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
| DR-10624 | DR-10624 | Phase 1 Clinical | Zhejiang Doer Biologics Corp | Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease; Metabolic Syndrome; Obesity; Diabetes Mellitus | Details |
| Isosteviol | ISV; STX-03 | Phase 2 Clinical | Stevia Pharma | Diabetes Mellitus, Type 2 | Details |
| Human glucagon(Shanghai Duomirui) | Phase 1 Clinical | Shanghai Duomirui Biotechnology Co Ltd | Hypoglycemia | Details | |
| Cotadutide | MEDI-0382 | Phase 3 Clinical | Medimmune Llc | Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Renal Insufficiency; Liver Cirrhosis; Hepatic Insufficiency; Obesity; Renal Insufficiency, Chronic; Diabetes Mellitus | Details |
| BI-456906 | BI-456906 | Phase 2 Clinical | Zealand Pharma A/S | Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Liver Cirrhosis; Liver Diseases; Obesity; Overweight | Details |
| Mazdutide | OXM-3; IBI-362; LY-3305677 | Phase 3 Clinical | Eli Lilly And Company | Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
| volagidemab | AMG-477; REMD-477 | Phase 2 Clinical | Amgen Inc | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucose Intolerance; Insulin Resistance; Hyperglycemia; Diabetes Mellitus | Details |
| Glucagon (Translational Research Institute for Metabolism and Diabetes, Florida) | Phase 1 Clinical | Translational Research Institute For Metabolism And Diabetes | Obesity | Details | |
| DD-01 | DD-01 | Phase 1 Clinical | Neuraly Inc, D&D Pharmatech | Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
| PB-718 | PB-718 | Phase 1 Clinical | Peg Bio Co Ltd | Non-alcoholic Fatty Liver Disease; Obesity | Details |
This web search service is supported by Google Inc.
A-Z
